

ACTIVATION OF HUMAN MACROPHAGES

Comparison of Other Cytokines with Interferon- $\gamma$

BY CARL F. NATHAN, THOMAS J. PRENDERGAST, MICHAEL E. WIEBE,  
E. RICHARD STANLEY, ERICH PLATZER, HEINZ G. REMOLD,  
KARL WELTE, BERISH Y. RUBIN, AND HENRY W. MURRAY

*From The Rockefeller University, the Division of Infectious Diseases of the Cornell University Medical College, the Lindsley F. Kimball Research Institute of the New York Blood Center, and the Developmental Hematopoiesis Laboratory of the Sloan-Kettering Institute for Cancer Research, New York, New York 10021; the Department of Microbiology and Immunology of the Albert Einstein School of Medicine, New York, New York 10461; and the Department of Medicine, Robert Breck Brigham Hospital, Harvard Medical School, Boston, Massachusetts 02115*

We recently reported that partially purified native interferon- $\gamma$  (nIFN $\gamma$ ) and pure recombinant interferon- $\gamma$  (rIFN $\gamma$ ) induced human macrophages to secrete large amounts of reactive oxygen intermediates when appropriately triggered, and to kill the intracellular protozoal pathogens *Toxoplasma gondii* (1) and *Leishmania donovani* (2). Taking these properties to define macrophage activation, all detectable macrophage-activating factor (MAF) in the supernatant of mitogen- or antigen-stimulated blood mononuclear cells was eliminated by anti-IFN $\gamma$  monoclonal antibody (1, 2). It thus appeared that IFN $\gamma$  was necessary and sufficient for macrophage activation by these supernatants. However, additional studies are needed to learn whether other cytokines may also have MAF activity.

The proliferative, endocytic, secretory, locomotive, and cytotoxic properties of macrophages can be influenced by IFN $\alpha$  (3, 4), IFN $\beta$  (4–6), colony stimulating factor type 1 (CSF-1) (7–9), colony stimulating factor for granulocytes and macrophages (GM-CSF) (10, 11), pluripotent colony stimulating factor (p-CSF),<sup>1</sup> and migration inhibitory factor (MIF) (12). Also worthy of study is interleukin 2 (IL-2), the only secretory product of the T cell other than IFN $\gamma$  currently available as the pure product of a cloned gene (13), and tumor necrosis factor (TNF) (14), whose potential for macrophage activation has not previously been examined. We studied highly purified preparations of each of the foregoing. Only IFN $\gamma$  enhanced both the H<sub>2</sub>O<sub>2</sub> secretion and antitoxoplasma activity of human macrophages.

---

This work was supported by National Institutes of Health grants CA22090, AI16963, AI12110, AI17920, HL25534, and contract N01-HB-0-2919, and by grants RF78021 from the Rockefeller Foundation, 103/1-1 from the Deutsche Forschungsgemeinschaft, and from the Gar Reichman Foundation. C. F. Nathan, to whom reprint requests should be addressed, is the recipient of a research career award from the Irma T. Hirsch Trust.

<sup>1</sup> K. Welte, E. Platzer, L. Lu, J. Gabrilove, R. Mertelsmann, and M. A. S. Moore. A CSF promoting clonal growth from early erythroid (BFU-E), multipotential (CFU-GEMM) and granulocyte-macrophage (CFU-GM) progenitors. Manuscript in preparation.

TABLE I  
Cytokines Used in This Study

Cytokine	$M_r$	Specific activity*	Purity	Source
rIFN $\gamma$	34,292	$2.6 \pm 0.4 \times 10^{6\ddagger}$	Pure	Genentech, So. San Francisco, CA
nIFN $\alpha$	17,800–20,000	$1.4 \times 10^8$	Pure	Leukocytes induced with Sendai virus. Affinity purified <sup>§</sup>
rIFN $\alpha$ A	19,219	$2 \times 10^8$	Pure	Hoffman-La Roche, Nutley, NJ (17)
rIFN $\alpha$ D	19,392	$2 \times 10^8$	Pure	Hoffman-La Roche (17)
rIFN $\beta$	19,987	$2 \times 10^8$	Pure	Hoffman-La Roche (17)
CSF-1		$4 \times 10^6$	~5%	Human urine, purified as in reference 20
GM-CSF		$3.8 \times 10^5$	Partial	Culture supernatant of T5637 bladder carcinoma cell line (footnote 1)
p-CSF		$1.5 \times 10^8$	Pure	As above, purified by DE52, AcA gel filtration, and reverse phase HPLC
MIF		Note <sup>¶</sup>	Note <sup>¶</sup>	T-T hybridoma concanavalin-stimulated supernate purified by salt fractionation, phenyl Sepharose chromatography, and ion exchange HPLC
TNF		$10^6$	Partial	Epstein-Barr virus-transformed B cell line supernate purified by sequential column chromatography (14)
nIL-2		$7 \times 10^4$	Partial	Genzyme, Inc., Norwalk, CT
rIL-2	15,421	$10^6$	Pure	Biogen, Cambridge, MA

\* U/mg protein. For IFN, international antiviral units. For other cytokines, units of bioactivity as defined in the cited references.

<sup>‡</sup> Based on antiviral assays performed by BYR as described (1) and protein measurements by the method of Lowry et al. (15) using a bovine serum albumin standard. Mean  $\pm$  SEM for 3 separate lots, including 1 from Biogen that was used in 1 experiment with equivalent results.

<sup>§</sup> Using the monoclonal antibody described in reference 16. Contains a mixture of subtypes.

<sup>¶</sup> Purified ~100-fold from the serum-free starting material. Negative for endotoxin by the limulus amoebocyte lysate assay. IFN $\gamma$  not detectable.

## Materials and Methods

Human monocyte-derived macrophages were assayed for H<sub>2</sub>O<sub>2</sub> release, adherent cell protein, and antitoxoplasma activity as described (1), except that the number of mononuclear cells plated ranged up to  $2 \times 10^6$  and in many experiments, the volume of culture medium was increased to 0.5 ml/well after the first day. The test media described in Table I were added on day 4, 5, or 6 and H<sub>2</sub>O<sub>2</sub> release tested 3 d later.

## Results

**H<sub>2</sub>O<sub>2</sub>-Releasing Capacity, Cell Shape, and Adherent Cell Protein.** Fig. 1 compares the ability of 11 cytokines to enhance the oxidative metabolism of human monocyte-derived macrophages. rIFN $\gamma$ , included as a positive control in each experiment, elevated macrophage H<sub>2</sub>O<sub>2</sub>-releasing capacity an average of eight-fold above that of cells cultured in medium alone. 50% of the maximal stimulation required  $\sim 1 \times 10^{-12}$  M rIFN $\gamma$  ( $\sim 0.1$  U/ml). The non- $\gamma$  IFNs were tested over a  $10^5$ -fold range of concentrations, up to  $10^4$  antiviral U/ml. Pure nIFN $\alpha$  (a mixture of subtypes) did not enhance H<sub>2</sub>O<sub>2</sub> release. In contrast to rIFN $\gamma$ , nIFN $\alpha$  at  $\geq 1,000$  U/ml decreased cell spreading and the amount of protein adherent to the coverslips (Table II), suggesting toxicity. Results were similar with pure rIFN $\alpha$ A, rIFN $\alpha$ D, and rIFN $\beta$ , except that rIFN $\alpha$ D had less effect on cell protein and no effect on cell shape.

Partially purified CSF-1 and GM-CSF did not enhance H<sub>2</sub>O<sub>2</sub> release. However, these preparations did interact with the macrophages, as evidenced by marked spreading of the cells and an increase in the adherent cell protein by a factor of  $1.25 \pm 0.48$  ( $n = 3$ ) for CSF-1 (8) and  $2.23 \pm 0.29$  ( $n = 5$ ) for GM-CSF. When




FIGURE 1.  $H_2O_2$  release by phorbol myristate acetate-challenged human macrophages after 3 d in the indicated cytokines. Means  $\pm$  SEM for the number of experiments noted above each point, each in triplicate with cells from a different donor. A unit of MIF is the amount in the active chromatographic fractions derived from 1 ml of starting material.

added from day 5 or 6 of culture, pure p-CSF affected neither  $H_2O_2$  release, cell shape, nor adherent cell protein (the latter was  $0.97 \pm 0.11$  times the control,  $n = 3$ ). TNF was similarly without effect. MIF-rich fractions increased  $H_2O_2$ -releasing capacity approximately fourfold above the control. Spreading and adherent cell protein also tended to increase, the latter by a factor of  $1.28 \pm 0.20$  ( $n = 5$ ). rIL-2 enhanced  $H_2O_2$ -releasing capacity slightly at  $10^4$  U/ml, but

TABLE II  
Effect of IFN $\gamma$ , IFN $\alpha$ , IFN $\beta$ , and IL-2 on Adherent Cell Protein

Test agent	Adherent cell protein (% of control)*		
	100 <sup>†</sup>	1,000 <sup>†</sup>	10,000 <sup>†</sup>
rIFN $\gamma$	125 $\pm$ 26 (8) <sup>‡</sup>	110 $\pm$ 20 (8)	Not done
nIFN $\alpha$	116 $\pm$ 33 (8)	84 $\pm$ 12 (8)	49 $\pm$ 5 (5)
rIFN $\alpha$ A	77 $\pm$ 22 (4)	83 $\pm$ 21 (3)	63 $\pm$ 14 (4)
rIFN $\alpha$ D	64 $\pm$ 3 (3)	96 $\pm$ 36 (3)	75 $\pm$ 30 (3)
rIFN $\beta$	86 $\pm$ 22 (5)	56 $\pm$ 18 (5)	46 $\pm$ 7 (5)
rIL-2	88 $\pm$ 9 (3)	99 $\pm$ 13 (4)	85 $\pm$ 13 (2)

\* Control values (cell protein on saline-rinsed coverslips after incubation in medium alone) averaged 23.9  $\pm$  6.6  $\mu$ g (13 experiments).

<sup>†</sup> U/ml.

<sup>‡</sup> Mean  $\pm$  SEM for the number of experiments in parentheses, each in triplicate.

TABLE III  
Comparison of IFN $\gamma$  with Other Cytokines for Induction of Antitoxoplasma Activity in Human Macrophages

Agent*	U/ml	% Toxoplasmas killed at 4–6 h	No. toxoplasmas/vacuole at 20 h
Medium	—	3.3 $\pm$ 1.6 (7) <sup>‡</sup>	6.1 $\pm$ 0.3 (9)
rIFN $\gamma$	100–300	42.9 $\pm$ 4.3 (7)	1.9 $\pm$ 0.1 (10)
nIFN $\alpha$	300–500 <sup>§</sup>	0.0 $\pm$ 0.0 (2)	5.2 $\pm$ 0.2 (2)
rIFN $\alpha$ A	300–500 <sup>§</sup>	1.0 $\pm$ 0.7 (2)	5.8 $\pm$ 0.2 (2)
rIFN $\alpha$ D	300–500 <sup>§</sup>	0.8 $\pm$ 0.7 (4)	5.1 $\pm$ 0.3 (5)
rIFN $\beta$	300–500 <sup>§</sup>	0.0 $\pm$ 0.0 (3)	5.0 $\pm$ 0.4 (4)
CSF-1	500	9.0 $\pm$ 4.2 (3)	5.4 $\pm$ 0.5 (3)
GM-CSF	500	2.8 $\pm$ 1.9 (4)	6.1 $\pm$ 0.3 (4)
MIF	1–30 <sup>¶</sup>	7.2 $\pm$ 3.0 (6)	5.9 $\pm$ 0.6 (6)
nIL-2	10–100	5.0 $\pm$ 5.0 (2)	4.6 $\pm$ 0.4 (2)
rIL-2	10–100	5.5 $\pm$ 3.3 (4)	4.8 $\pm$ 0.3 (4)

\* Macrophages were incubated with the indicated cytokines for 3 d before being washed and challenged with toxoplasmas. The course of infection was followed in control medium for the next 20 h.

<sup>‡</sup> Mean  $\pm$  SEM for the number of experiments in parentheses, each in duplicate.

<sup>§</sup> Higher concentrations were not tested because rounding up of the macrophages interfered with counting intracellular organisms.

<sup>¶</sup> As defined in the legend to Fig. 1.

this effect was eliminated by the addition of monoclonal antibody against IFN $\gamma$ .

**Antitoxoplasma Activity.** Under the conditions tested, none of the agents except rIFN $\gamma$  conferred on macrophages the ability to kill *T. gondii* or to inhibit its intracellular replication (Table III).

## Discussion

Therapy is now feasible with purified products of cloned genes. This heightens interest in the identification of cytokines that augment the antimicrobial activity of host cells. Recent studies establish that IFN $\gamma$  promotes host cell-mediated inhibition of a variety of nonviral pathogens, such as toxoplasma (1, 19), leishmania (2), chlamydia (20), rickettsia (21), and malaria.<sup>2</sup> However, it is not clear whether other cytokines can also enhance the nonviral antimicrobial activity of human macrophages or its biochemical correlate, their capacity to secrete reactive oxygen intermediates (22). In the present work we tested individually many of

<sup>2</sup> C. F. Ockenhouse, S. Schulman, and H. L. Shear. Induction of crisis forms in the human malaria parasite, *Plasmodium falciparum*, by gamma-interferon activated, monocyte-derived macrophages. Submitted for publication.

the cytokines that affect macrophages, with special emphasis on non- $\gamma$  IFNs. Our findings are consistent with earlier studies in which all detectable MAF activity was depleted from unfractionated, polyclonally activated mononuclear cell supernatants by monoclonal antibody to IFN $\gamma$  (1, 2, 20). Thus, when tested in vitro in partially or highly purified form and over a wide range of concentrations, the following affected neither the antitoxoplasma activity of human macrophages nor, with one exception, their secretion of H<sub>2</sub>O<sub>2</sub>: nIFN $\alpha$ , rIFN $\alpha$ A, rIFN $\alpha$ D, rIFN $\beta$ , CSF-1, GM-CSF, p-CSF, MIF, nIL-2, rIL-2, and TNF.

MIF-rich preparations increased macrophage H<sub>2</sub>O<sub>2</sub> secretion above control approximately threefold less than rIFN $\gamma$ . It will be of interest to test the ability of MIF-treated macrophages to kill parasites more susceptible to oxidative injury than toxoplasmas (22). We have not yet studied the effect of pure MIF or of monoclonal anti-MIF antibodies, and thus have not proven that MIF was the active factor from the T-T hybridoma used here. It also remains to be seen if MAF is associated with the MIF produced by uncloned, nontransformed lymphocytes. Further study of MIF is underway.

Thus far, IFN $\gamma$  appears to be the only known host-derived substance with the ability to activate both the oxidative metabolism and antitoxoplasma activity of human macrophages.

### Summary

Cytokines affecting mononuclear phagocytes were screened for activation of human macrophages to secrete H<sub>2</sub>O<sub>2</sub> and kill toxoplasmas. In contrast to recombinant interferon- $\gamma$  (rIFN $\gamma$ ), the following factors, tested in partially or highly purified form and over a wide range of concentrations, did not augment these functions: native interferon- $\alpha$  (nIFN $\alpha$ ), rIFN $\alpha$ A, rIFN $\alpha$ D, rIFN $\beta$ , colony stimulating factor (type 1) (CSF-1), CSF for granulocytes and macrophages (GM-CSF), pluripotent CSF (p-CSF), tumor necrosis factor (TNF), native interleukin 2 (nIL-2), and rIL-2. Partially purified migration inhibitory factor (MIF) enhanced H<sub>2</sub>O<sub>2</sub>-releasing capacity submaximally without inducing antitoxoplasma activity, and warrants further study.

We thank Drs. Costa Sevastopoulos (Genentech, Inc.), Patrick Trown (Hoffman-La Roche, Inc.), and Seth Rudnick (Biogen, Inc.), for gifts of reagents. Critical review of the manuscript by Dr. Zanvil Cohn is greatly appreciated.

*Received for publication 18 April 1984.*

### References

1. Nathan, C., H. W. Murray, M. E. Wiebe, and B. F. Rubin. 1983. Identification of interferon- $\gamma$  as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J. Exp. Med.* 158:670.
2. Murray, H. W., B. F. Rubin, and C. D. Rothermel. 1983. Killing of intracellular *Leishmania donovani* by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon- $\gamma$  is the activating lymphokine. *J. Clin. Invest.* 72:1506.
3. Hovi, T., O. Saksela, K. Linnavuori, A. Vaheri, and K. Cantell. 1981. Activation of monocyte functions by interferons. *In* The Biology of the Interferon System. E. De Maeyer, G. Galasso, and H. Schellekens, editors. Elsevier/North-Holland, New York. pp. 217-220.

4. Schultz, R. M. 1982. Synergistic activation of macrophages by lymphokine and lipopolysaccharide: evidence for lymphokine as the primer and interferon as the trigger. *J. Interferon Res.* 2:459.
5. Jett, R., A. Mantovani, and R. B. Herberman. 1980. Augmentation of human monocyte-mediated cytotoxicity by interferon. *Cell. Immunol.* 54:425.
6. Vogel, S. N., D. S. Finbloom, K. E. English, D. L. Rosenstreich, and S. E. Langreth. 1983. Interferon-induced enhancement of macrophage Fc receptor expression:  $\beta$ -interferon treatment of C3H/HeJ macrophages results in increased numbers and density of Fc receptors. *J. Immunol.* 130:1210.
7. Hamilton, J. A., E. R. Stanley, A. W. Burgess, and R. K. Shadduck. 1980. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. *J. Cell. Physiol.* 103:435.
8. Tushinski, R. J., I. T. Oliver, L. J. Guilbert, P. W. Tynan, J. R. Warner, and E. R. Stanley. 1982. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. *Cell.* 28:71.
9. Wing, E. J., A. Waheed, R. K. Shadduck, L. S. Nagle, and K. Stephenson. 1982. Effect of colony-stimulating factor on murine macrophages. Induction of antitumor activity. *J. Clin. Invest.* 69:270.
10. Handman, E., and A. W. Burgess. 1979. Stimulation by granulocyte-macrophage colony-stimulating factor of *Leishmania tropica* killing by macrophages. *J. Immunol.* 122:1134.
11. Kurland, J. I., L. M. Pelus, P. Ralph, R. S. Bockman, and M. A. S. Moore. 1979. Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor formation. *Proc. Natl. Acad. Sci. USA.* 76:2326.
12. Remold, H. G., P. L. McCarthy, Jr., and A. D. Mednis. 1981. Purification of guinea pig pH 3 migration inhibitory factor. *Proc. Natl. Acad. Sci. USA.* 78:4088.
13. Taniguchi, T., H. Matsui, T. Fujita, C. Takaoka, N. Kashima, R. Yoshimoto, and J. Hamuro. 1983. Structure and expression of a cloned cDNA for human interleukin 2. *Nature (Lond.)*. 302:305.
14. Williamson, B. D., E. A. Carswell, B. Y. Rubin, J. S. Prendergast, and L. J. Old. 1983. Human tumor necrosis factor produced by B cell lines: synergistic cytotoxic interaction with human interferons. *Proc. Natl. Acad. Sci. USA.* 80:5397.
15. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193:265.
16. Secher, D. S., and D. C. Burke. 1980. A monoclonal antibody for large-scale purification of a human leukocyte interferon. *Nature (Lond.)*. 285:446.
17. Rehberg, E., B. Kelder, E. G. Hoal, and S. Pestka. 1982. Specific molecular activities of recombinant and hybrid leukocyte interferons. *J. Biol. Chem.* 257:11497.
18. Das, S. K., E. R. Stanley, L. J. Guilbert, and L. W. Forman. 1981. Human colony-stimulating factor (CSF-1) radioimmunoassay: resolution of three subclasses of human colony stimulating factors. *Blood.* 58:630.
19. Pfefferkorn, E. R. 1984. Interferon  $\gamma$  blocks the growth of *Toxoplasma gondii* in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc. Natl. Acad. Sci. USA.* 81:908.
20. Rothermel, C. D., B. Y. Rubin, and H. W. Murray. 1983.  $\gamma$ -interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular *Chlamydia psittaci* replication. *J. Immunol.* 131:2542.
21. Turco, J., and H. Winkler. 1983. Cloned mouse interferon- $\gamma$  inhibits the growth of *Rickettsia prowazekii* in cultured mouse fibroblasts. *J. Exp. Med.* 158:2159.
22. Nathan, C. F. 1983. Mechanisms of macrophage antimicrobial activity. *Trans. R. Soc. Trop. Med. Hyg.* 77:620.